Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2118436 drug-drug interaction and pharmacokinetics study in BRAF-mutant solid tumors
2011-004436-61Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dabrafenib + trametinib in Nonhematologic neoplasms and cutaneous malignancy (4 arms), sponsored by GSK. Primary endpoint: S-warfarin pharmacokinetics with and without dabrafenib. Started Mar 2012; status: completed.
02
Drugs
dabrafenib + trametinib
03
Conditions
Nonhematologic neoplasmscutaneous malignancy
Beyond the preview
Go deeper on 2011-004436-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004436-61.